1、教育经历
(1) 2009/09-2014/06， 中国药科大学，药物化学专业， 博士
(2) 2005/09-2009/07， 中国药科大学，基础药学理科基地班，学士
2、工作经历
(1) 2017/07 至今， 中国药科大学，药学院，副教授
(2) 2014/06-2017/06， 中国药科大学，药学院，讲师
3、学术荣誉
2022/05，江苏高校“青蓝工程”优秀骨干教师
2021/03，江苏省青年岗位能手
2020/08，江苏省五一创新能手
2020/08，江苏省技术能手
4、学术兼职
2022/06，药学与临床研究杂志青年编委
（1）表观遗传修饰酶相关调控剂的设计与合成
（2）抗肿瘤小分子化合物的合成与成药性评价
（1）国家自然科学基金委员会，面上项目，82173673，基于靶标结构设计、合成高选择性ALKBH5抑制剂并探索其在肿瘤疾病中的应用，2022-01-01 至 2025-12-31，55万元，在研，主持
（2）国家自然科学基金委员会，面上项目，81872799，通过构象调控方法设计MLL1-WDR5蛋白-蛋白相互作用小分子抑制剂并探索其在血液肿瘤中的应用，2019-01-01 至 2022-12-31，57万元，在研，主持
（3）国家自然科学基金委员会，青年基金，81502915 全新骨架组蛋白甲基转移酶G9a抑制剂的构效关系、结合模式及作用机制研究，2015-01-01 至 2018-12-31，21.28万元，结题，主持
（4）江苏省自然科学基金委员会，面上项目，BK20191321，新型靶向MLL1-WDR5治疗血液肿瘤的小分子抑制剂的设计、合成及生物学研究，2019-07-01 至 2022-06-31，10万元，在研，主持
1.Lingyue Zhao, Qian Yang , Yiqun Tang, Qidong You* and Xiaoke Guo*, Design, synthesis, and biological evaluation of arylmethylpiperidines as Kv1.5 potassium channel inhibitors, J. Enzym. Inhib. Med. Chem. 2022, 37(1), 462-471. (IF = 5.756)
2.Weilin Chen, Xin Chen, Dongdong Li, Jianrui Zhou, Zhengyu Jiang*, Qidong You* and Xiaoke Guo*, Discovery of DDO-2213 as a Potent and Orally Bioavailable Inhibitor of the WDR5–Mixed Lineage Leukemia 1 Protein–Protein Interaction for the Treatment of MLL Fusion Leukemia, J. Med. Chem. 2021, 64(12), 8221-8245. (IF = 8.039)
3.Xin Chen, Junjie Xu, Xianghan Wang, Guanlu Long, Qidong You* and Xiaoke Guo*, Targeting WD Repeat-Containing Protein 5 (WDR5): A Medicinal Chemistry Perspective, J. Med. Chem. 2021, 64(15), 10537-10556. (IF = 8.039)
4.Weilin Chen, Xin Chen, Dongdong Li, Xianghan Wang, Zhengyu Jiang*, Qidong You* and Xiaoke Guo*, Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity, Eur. J. Med. Chem., 2021, 223, 113677. (IF = 7.088)
5.Wei-Lin Chen, Dong-Dong, Xin Chen, Ying-Zhe Wang, Jun-Jie Xu, Zheng-Yu Jiang*, Qi-Dong You*, Xiao-Ke Guo*, Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction, Eur. J. Med. Chem., 2020, 188, 112027. (IF = 7.088)
6.Jing Gu, Jun Xu, Qi-Dong You*, Xiao-Ke Guo*, Recent developments of small molecules targeting RNA m6A, Eur. J. Med. Chem., 2020, 196, 112325. (IF = 7.088)
7.Wei-Lin Chen, Dong-Dong Li, Zhi-Hui Wang, Xiao-Li Xu, Xiao-Jin Zhang, Zheng-Yu Jiang, Xiao-Ke Guo*, Qi-Dong You*, Design, synthesis, and initial evaluation of affinity-based small molecular probe for detection of WDR5, Bioorg. Chem., 2017, 76, 380-385. (IF = 5.307)
8.Wei-Lin Chen, Zhi-Hui Wang, Tao-Tao Feng, Dong-Dong Li, Chu-Hui Wang, Xiao-Li Xu, Xiao-Jin Zhang, Qi-Dong You*, Xiao-Ke Guo*, Discovery, design and synthesis of 6H-anthra[1,9-cd]isoxazol-6-one scaffold as G9a inhibitor through a combination of shape-based virtual screening and structure-based molecular modification, Bioorg. Med. Chem., 2016, 24, 6102-6108. (IF = 3.461)
9.Dong-Dong Li, Wei-Lin Chen, Zhi-Hui Wang, Yi-Yue Xie, Xiao-Li Xu, Zheng-Yu Jiang, Xiao-Jin Zhang, Qi-Dong You*, Xiao-Ke Guo*, High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity, Eur. J. Med. Chem., 2016, 124, 480-489. (IF = 7.088)
10.Tao-Tao Feng, Dong-Dong Li, Hai Wang, Jian Zhuang, Fang Liu, Qichao Bao, Yonghua Lei, Wei-Lin Chen, Xiao-Jin Zhan, Xiao-Li Xu, Hao-Peng Sun, Qi-Dong You*, Xiao-Ke Guo*, Novel 5-carboxy-8-HQ based histone demethylase JMJD2A inhibitors: Introduction of an additional carboxyl group at the C-2 position of quinoline, Eur. J. Med. Chem., 2015, 105, 145-155. (IF = 7.088)
